2-(n-cyclohexylamino)ethanesulfonic acid has been researched along with Hepatitis E in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berastegui, C; Bilbao, I; Buti, M; Castells, L; Esteban, R; Forns, X; García-Eliz, M; Imaz, A; Lens, S; Llaneras, J; Martínez-Camprecios, J; Martínez-Valle, F; Navarro, J; Ortí, G; Perelló, M; Prieto, M; Rando-Segura, A; Riveiro-Barciela, M; Roade, L; Robles-Alonso, V; Rodríguez-Diez, B; Rodríguez-Frías, F; Ventura-Cots, M; Vidal-González, J | 1 |
1 other study(ies) available for 2-(n-cyclohexylamino)ethanesulfonic acid and Hepatitis E
| Article | Year |
|---|---|
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
Topics: Adult; Hepatitis Antibodies; Hepatitis E; Hepatitis E virus; Hepatitis, Chronic; HIV Infections; Humans; Immunoglobulin G; Immunosuppressive Agents; Liver Cirrhosis; MTOR Inhibitors; Prospective Studies; Risk Factors; RNA, Viral; Transaminases | 2023 |